ROSSARI NSI Week ended 07 Aug 2026

Weekly Investor Report

Rossari Biotech Limited · Basic Materials · Specialty Chemicals

Open interactive chart View report data
Latest close 514.0 INR
1.9% latest week
Weekly setup

Mixed setup

The weekly trend is active. Price is 2.2% above the Trend Line and sits at 44.1% of its 52-week range. The latest completed week returned 1.9%, after a -2.0% four-week move. The latest factor snapshot indicates quality ranks weakly versus its universe; growth is moderate; valuation is neither clearly cheap nor expensive. The latest news-sentiment score is 52/100.

Setup score 38 out of 100
Latest Close 514.0 INR 7 Aug 2026
1W Return 1.9% latest completed week
4W Return -2.0% short-term follow-through
12W Return 1.4% quarterly tape
Trend Breadth 3.8% 2 of 52 weeks active
Volume Ratio 1.4x vs 13-week average
What is working
  • The trend backdrop is active with a 2-week active streak.
  • Price is above the Trend Line, keeping the weekly tape constructive.
  • Activity pressure is positive on the latest completed week.
What could go wrong
  • Price is below Fair Value, so the market is still discounting the latest tape.
  • Activity pressure is weak, so confirmation is not yet broad enough.
  • The share remains more than 20% below its 52-week high.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through 1.9% Latest completed week; four-week move -2.0%. Indicator stack 9/48 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. News sentiment 52/100 26 relevant articles in the latest sentiment read.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is active. Price is 2.2% above the Trend Line and sits at 44.1% of its 52-week range. The latest completed week returned 1.9%, after a -2.0% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 1.4x the 13-week average. Participation is around or above normal and provides reasonable confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul 7 Aug
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.3112-week average 0.29

12-week confirmation

Trend active2/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure12/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership1/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.31Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -2.0% over four weeks, 1.4% over 12 weeks, and -20.7% over one year. The current trend has remained active for 2 consecutive weeks.

Performance by holding period

1W1.9%
4W-2.0%
12W1.4%
26W-1.1%
52W-20.7%
Active trend streak2 weeks
Active weeks in one year2
Trend breadth3.8%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure0.24Latest activity-pressure read.
Pressure change-74.8%Four-week change in activity pressure.
Leadership-6.18Latest relative-leadership reading.
RS change-16.7%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality ranks weakly versus its universe; growth is moderate; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 09 Aug 2026 Financial statements through 31 Mar 2026 Field coverage 94% Model confidence 88%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength38/100Blend of value, momentum, and quality. Underlying universe rank 63; rank 1 is best.
Value72/100Relative valuation strength. Underlying universe rank 29; rank 1 is best.
Quality19/100Profitability and accounting quality. Underlying universe rank 82; rank 1 is best.
Momentum20/100Medium-term price momentum. Underlying universe rank 81; rank 1 is best.
Growth64/100Revenue and earnings growth. Underlying universe rank 37; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Value-quality framework68/100Value and quality alignment from the Sharemaestro SVQF framework.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
19.4x
Price divided by trailing earnings.
Price / sales
1.2x
Market value relative to trailing revenue.
EV / EBITDA
10.4x
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-6.2%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
30.1%
Gross profit retained from each unit of revenue.
Operating margin
8.6%
Operating profit retained from revenue.
Free-cash-flow margin
-8.4%
Free cash flow generated from revenue.
Return on invested capital
9.0%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
15.4%
Latest one-year revenue growth.
EPS growth
9.4%
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
3/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
0.1%
Cash dividends relative to market value.
Buyback yield
-0.0%
Net share repurchases relative to market value.
Shareholder yield
0.1%
Dividend yield plus net buyback yield.
Net debt / EBITDA
1.2x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Insider activity-

No recent insider transactions are stored for this company.

News sentiment52/100

Weighted news tone is neutral across 26 relevant articles.

2 positive · 22 neutral · 2 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-25.5%Distance below the 52-week high.
13-week volatility4.9%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher13 of 2613 weeks finished lower.
Best week+13.6%Week of 8 May.
Worst week-7.8%Week of 24 Jul.
Latest week+1.9%Week of 7 Aug.

Shape of recent returns

Strong gains5
Modest gains8
Flat weeks0
Modest losses5
Sharp losses8
Recent vol4.9%13-week weekly-return volatility.
Base vol4.9%52-week weekly-return volatility.
Up/down split25/27Count of positive and negative weeks in the 52-week window.
Average skew3.6% / -4.0%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape35/100

Trend, activity pressure, participation, and risk combine to a 35/100 tape read.

 Indicator analysis41/100

Latest 12-week confirmation: trend 2/12, activity pressure 12/12, relative leadership 1/12.

Activity pressure 0.31; No reversal markers Factors36/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 74; Small Cap Core rank 39 SVQF68/100

Value and quality alignment from the Sharemaestro SVQF framework.

Composite rank 503.0 of 1576 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Sentiment52/100

Weighted news tone is neutral across 26 relevant articles.

Rossari Biotech withdraws from Nirmal Bang investor meet on Aug 10 Insiders50/100

No recent insider transaction evidence is stored.

 Earnings50/100

No stored earnings event is currently attached to this ticker.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
7 Aug 2026514.0 INR1.9%503.0 INR691.8 INR0.24-6.18549.3KOn
31 Jul 2026504.3 INR3.0%504.7 INR693.9 INR0.40-7.68405.6KOn
24 Jul 2026489.8 INR-7.8%507.3 INR696.0 INR0.62-8.64361.6KOff
17 Jul 2026531.5 INR1.4%510.2 INR698.5 INR0.88-3.84524.6KOff
10 Jul 2026524.2 INR0.6%511.5 INR700.7 INR0.93-5.29339.5KOff
3 Jul 2026521.1 INR-2.5%513.5 INR702.9 INR0.86-6.5858.3KOff
26 Jun 2026534.3 INR-4.6%516.3 INR705.1 INR0.84-3.800Off
19 Jun 2026560.4 INR11.3%518.5 INR707.2 INR0.820.69819.0KOff
12 Jun 2026503.5 INR-4.4%520.3 INR709.0 INR0.75-8.29115.9KOff
5 Jun 2026526.5 INR1.5%524.5 INR711.2 INR0.80-3.5353.5KOff
29 May 2026518.8 INR-1.0%527.8 INR713.3 INR0.97-6.04519.7KOff
22 May 2026524.0 INR3.4%531.9 INR714.8 INR1.01-6.16644.9KOff
15 May 2026506.6 INR-6.9%536.1 INR716.1 INR1.07-9.30804.5KOff
8 May 2026544.0 INR13.6%541.6 INR717.5 INR1.02-5.312.9MOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.

Evidence context